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Histone deacetylase inhibitors (HDACIs) interfere with the epigenetic process of histone acetylation and
are known to have analgesic properties in models of chronic inﬂammatory pain. The aim of this study was
to determine whether these compounds could also affect neuropathic pain. Different class I HDACIs were
delivered intrathecally into rat spinal cord in models of traumatic nerve injury and antiretroviral drug–
induced peripheral neuropathy (stavudine, d4T). Mechanical and thermal hypersensitivity was attenu-
ated by 40% to 50% as a result of HDACI treatment, but only if started before any insult. The drugs globally
increased histone acetylation in the spinal cord, but appeared to have no measurable effects in relevant
dorsal root ganglia in this treatment paradigm, suggesting that any potential mechanism should be
sought in the central nervous system. Microarray analysis of dorsal cord RNA revealed the signature of
the speciﬁc compound used (MS-275) and suggested that its main effect was mediated through HDAC1.
Taken together, these data support a role for histone acetylation in the emergence of neuropathic pain.
 2013 International Association for the Study of Pain. Published by Elsevier B.V.1. Introduction
Although chronic neuropathic pain remains an area of consider-
able unmet clinical need [36], our view of the underlying pathology
has shifted considerably over the past 2 decades. It was initially
considered a neurophysiological issue – excessive neuronal activity
in speciﬁc pathways. Currently, it is more usually discussed in
terms of maladaptive plasticity rooted in altered transcriptional
expression, and indeed there are now a very large number of
examples of such change [38,43]. Yet, despite a wealth of expres-
sion studies, it is still unclear how these processes are coordinated.
One possibility is that there is involvement of epigenetic mecha-
nisms, such as histone acetylation.
Acetylation of histone lysine residues, such as lysine residue 9
(H3K9ac), relaxes chromatin structure, recruits and stabilizes chro-
matin remodeling enzymes, including transcription factors [51],
and promotes transcriptional elongation [47]. The process is con-trolled through the dynamic interplay of histone acetyltransferases
(HATs) and histone deacetylase (HDAC) enzymes. HDACs ﬁrst
aroused interest in clinical research when they were discovered
to be of importance in cancer, with their inhibition having chemo-
therapeutic effects [6,42]. In the nervous system, they have since
been shown to be involved in many disease models (eg, of neuro-
degenerative disorders [15] and depression [19]), as well as in fun-
damental cellular processes, such as neuronal plasticity [29,46].
In chronic pain, studies of HDACs and their inhibitors are only
just beginning to emerge [20]. Sodium valproate, which interferes
with HDACs as well as the GABAergic system, has been shown to
be an effective analgesic under some circumstances in rodents
[41,61] and, more controversially, in humans [1,24]. Pan-HDACIs,
such as trichostatin A and vorinostat, are claimed to affect visceral
hypersensitivity [58] as well as morphine-related phenomena,
such as tolerance-induced hyperalgesia [40] and conditioned place
preference [5]. Finally, the most well-studied, and hence perhaps
the most convincing paradigm in this context has been to admin-
ister HDACIs in models of acute inﬂammatory pain (complete
Freund’s adjuvant or formalin). Three independent groups have
reported various class I selective- and pan-HDAC compounds
to reduce rodents’ nociceptive responses, whether delivered
Fig. 1. Intrathecal histone deacetylase inhibitor HDACI treatment improved mechanical hypersensitivity after peripheral nerve injury. (A) A summary of the percentage
difference between ipsilateral and contralateral paw withdrawal thresholds (in grams) collected across 4 independent experiments (n = 36, n = 14, n = 15, and n = 11 for the
respective treatment groups). Compared with vehicle, delivery of HDACI (MS-275 at 30 nmol/d, MS-275 at 60 nmol/d, MGDC0103 at 60 nmol/d) signiﬁcantly reduced
withdrawal thresholds (as measured by automatic von Frey) in nerve-injured rats. Some of the raw data are displayed in parts B through D. (B) Intrathecal delivery of MS-275
(30 nmol/d via an osmotic pump) improved mechanical hypersensitivity after L5 spinal nerve transection: repeated-measures analysis of variance (ANOVA) (n = 6) with
baseline as a covariate; main effect of drug (F1,9 = 3.73, P < .001); interaction between drug  day (F2,18 = 36.4, P = .045). Drug delivery started 5 days before the injury and did
not cause any change in baseline withdrawal thresholds (BL + D). (C) MS-275 also signiﬁcantly increased von Frey withdrawal thresholds after partial sciatic nerve ligation:
repeated-measures ANOVA (n = 7), main effect of drug (F2,19 = 3.785, P = .041). (D) A different class I HDACI (MGCD0103) had similar analgesic effects after L5 spinal nerve
transection. Repeated-measures ANOVA (n = 6, vehicle and 60-nmol dose, n = 4, 30-nmol dose) with baseline as a covariate, main effect of drug (F2,12 = 4.902, P = .028),
interaction between drug  injury (F2,12 = 4.341, P = .038). (E) Area under the curve measurements for the 3 graphs (B–D), with stars indicating signiﬁcant differences at
P < .005 (independent samples t tests). BL = baseline; BL + D = baseline measured while drugs were delivered intrathecally; pi = post-injury; SNT = L5 spinal nerve transection;
SNL = partial sciatic nerve ligation. Error bars indicate SEM. Stars designate individual days on which the difference between drug and vehicle treatment was particularly
striking and survived Bonferroni post hoc tests (P < .05).
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Fig. 2. Intrathecal (HDACI) treatment attenuated mechanical hypersensitivity in a
more clinically relevant model of antiretroviral (d4T)–induced neuropathy. HDACI
pretreatment (MS-275 at 30 nmol/d) was delivered for 7 days, followed by
induction of neuropathy using 2 tail vein injections of the antiretroviral drug d4T.
The presence of the inhibitor signiﬁcantly reduced mechanical hypersensitivity:
repeated-measures ANOVA (n = 7), interaction between day  drug (F5,60 = 5.002,
P = .028). Stars designate individual days on which the difference between drug and
vehicle treatment was particularly striking and survived Bonferroni post hoc tests
(P < .05).
Fig. 3. HDACI treatment improved thermal hypersensitivity after neuropathic
injury. In 2 separate experiments, pretreatment with intrathecal MS-275 was found
to increase withdrawal thresholds after nerve injury on a radiant heat paw
withdrawal assay. (A) A 30-nmol/d dose: repeated-measures ANOVA (n = 6), main
effect of drug (F1,11 = 5.67, P = .036). (B) A 60-nmol/d dose: repeated-measures
ANOVA (n = 6), main effect of drug (F1,11) = 6.265, P = .029). Insets show area under
the curve measurements (independent-sample t tests, ⁄P < .05, #P = 0.1).
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region of the raphe nuclei [2,12,13,65].
There is evidence from expression studies that histone acetyla-
tion could also be relevant in neuropathic pain [35,65]. However, a
clear demonstration that selective interference with HDAC activity
can affect this type of chronic pain condition is still lacking. The
present study attempted to address this issue using chronic intra-
thecal delivery of 2 different class I selective HDACIs (MS-275 and
MGCD0103) into the spinal cord of rats. Animals were subjected to
1 of 2 traumatic nerve injury models (partial sciatic nerve ligation
or L5 spinal nerve transection) or to a more clinically relevant
model of antiretroviral drug–induced neuropathy [32]. In all cases,
increased histone acetylation was observed in the spinal cord and
behavioral hypersensitivity was reduced signiﬁcantly, indicating
that HDACs play a role in the emergence of neuropathic pain
conditions.
2. Materials and methods
2.1. Animals
Adult male Wistar rats were used for all experiments (Charles
River, Margate, UK). They were housed under standard conditions
(12-hour light/dark cycle, lights on between 7:00 am and
7:00 pm, in groups of 4–6) and were experimentally naive before
any testing. At the time of surgery, animals weighed between
220 and 250 g. All treatment and care of animals was in accordance
with the United Kingdom Animals Scientiﬁc Procedures Act (1986).
2.2. Behavioral experiments
At the beginning of all behavioral studies, rats were randomized
into groups using a list randomizer (random.org), and any subse-
quent testing was performed by an experimenter who was blind
to the assignment. F.D. and J.G. carried out behavioral tests after
nerve injury, whereas W.H. carried out behavior after antiretroviral
drug therapy in a different department, controlling to some extent
for variables that are known to affect behavioral outcome (experi-
menter and testing environment) [11]. Animals were onlyexcluded if they died during the surgery or if, on dissection, the
surgery was determined to be ﬂawed (ie, L4 spinal nerve transec-
tion, instead of L5, occurred in 2 of 48 cases). Behavioral results
were not analyzed until after the completion of testing and the
application of the dissection exclusion criterion.
2.2.1. Mechanical hypersensitivity
A dynamic plantar esthesiometer (Ugo Basile, Milan, Italy) was
used to assess mechanical sensitivity thresholds in rats. A probe
was applied with increasing force to the plantar surface of each
paw (1-50 g, ramping up over 20s), and withdrawal thresholds
were measured in triplicate. Before the start of testing, the animals
were habituated to the experimenter and the apparatus. Baseline
testing was performed twice before implantation of the intrathecal
catheter, after which at least 1 further baseline measure was col-
lected while the drug was infused. No change was observed from
the baseline before and after drug treatment in healthy animals.
After creating the neuropathic lesion, animals were tested at a
minimum of 3 time points while the drug was still being infused.
Different esthesiometers were used after nerve injury and after
d4T, leading to different baseline measurements (Fig. 1 vs Fig. 2),
and in the case of nerve injury, the esthesiometer was serviced be-
tween completed experiments, again leading to different baselines
in Figure 1B vs C and D.
2.2.2. Thermal hypersensitivity
A Hargreaves’ apparatus (Ugo Basile) was used to focus an
infrared beam on the plantar surface of each paw, and the time
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Values were collected in triplicate for each paw. The experimental
design was as described previously for von Frey testing. The data
for the 2 different graphs (Fig. 3A and B) were collected at different
times in 2 separate experiments, rendering the direct comparison
of absolute baseline measures impossible.
2.3. Surgery
Intrathecal catheters connected to Alzet osmotic pumps (ﬂow
rate of 0.25 lL/h for 28 days or 0.5 lL/h for 14 days) were im-
planted in rats under medetomidine hydrochloride (0.25 mg/kg)
and ketamine (60 mg/kg) anesthesia. A laminectomy was per-
formed at T10–12 and 2 cm of the catheter was inserted caudal
to the opening beneath the dura so that its tip lay at the L2–3 level
of the spinal cord. The pump was placed subcutaneously on the
animal’s back.
Subsequent nerve injury was performed under isoﬂurane. For
partial sciatic nerve ligations [49], the sciatic nerve was exposed
at mid-thigh level, above any branching, and approximately two-
thirds were tightly ligated with a 4–0 suture. For L5 spinal nerve
transections [16], an incision was made to access L5–6 spinal pro-
cesses. A third of the L6 transverse process was removed, and the
underlying L5 spinal nerve was ligated and transected distal to
the suture.
For experiments reported in Figures 1–3, pumps were placed at
least 5 days before nerve injury or d4T injections to allow ample
pretreatment with HDACI. To test whether HDACIs could rescue al-
ready established pain (Fig. 4), the catheter was implanted but left
unconnected. Animals were left to recover and tested for any
changes in sensitivity threshold. Nerve injury was then carried
out, and at the end of the surgery, unprimed Alzet pumps were
hooked up to the catheter. According to the pump manufacturer,
the drug should take approximately 24 hours to reach the central
nervous system without priming.
2.4. Antiretroviral-induced neuropathy
Induction of peripheral neuropathy using the antiretroviral
drug stavudine (d4T) has been previously described [32]. Brieﬂy,
50 mg/kg d4T (a gift from Pﬁzer Ltd., made by ZereneX Molecular
Limited, Greater Manchester, UK) was delivered intravenously intoFig. 4. HDACI treatment did not reverse already established hypersensitivity.
Pumps were connected immediately after the nerve injury was carried out,
resulting in the drug reaching the spinal cord 24 hours after the initial insult.
No effect on von Frey thresholds was observed with this treatment paradigm.
SNT = spinal nerve transaction.the tail vein of rats while they were under brief general anesthesia.
Two injections were administered, separated by a 4-day gap.
Behavioral testing for hind paw mechanical hypersensitivity was
carried out 6, 9, and 12 days after the ﬁrst d4T injection.
2.5. Drugs
HDACIs were purchased from Selleck Chemicals (Houston, TX)
and administered in Alzet mini-pumps over a period of 2 or
4 weeks (models 2002 or 2004; Charles River Laboratories, Mar-
gate, UK). Both MS-275 and MGCD0103 were administered at 30
or 60 nmol/d. The drugs were dissolved in 30% dimethyl sulfoxide
(DMSO) in saline solution, which was also used as a vehicle to con-
trol for any adverse effects of the DMSO solvent. The relatively high
DMSO concentration was required to ensure solubility of the com-
pounds, but would have been diluted on delivery (0.5 or 0.25 lL/h,
administered into much larger volumes of cerebral spinal ﬂuid)
and has been previously shown to have no effect on nociceptive
processing when administered intrathecally [18]. The results pre-
sented here were consistent with this: no signiﬁcant changes in
thermal or mechanical sensitivity thresholds were observed be-
tween naive rats (baseline, BL) and pump-implanted, uninjured
rats (baseline + drug [BL + D]) with vehicle (or indeed HDACI)
treatment. Moreover, saline solution or HDACI, both in 30% DMSO,
did not affect the contralateral paw at any point (data not shown),
and when pumps where implanted after the injury, no signiﬁcant
behavioral changes could be observed before or after nerve tran-
section (Fig. 4).
2.6. Dissection
After the behavioral experiments, at day 14 after injury or ﬁrst
d4T injection, rats were killed and spinal cord and DRG tissue was
dissected and snap-frozen in liquid nitrogen. Spinal nerves were
followed up from their respective ganglia to ensure consistent dis-
section of spinal cord segments L4–6. The open book method was
used to isolate dorsal ipsilateral and contralateral segments.2.7. Western blots
Proteins were homogenized in lysis buffer (2% Empigen, 3 mM
DTT, 1 mM sodium orthovanadate, 5 mM sodium ﬂuoride, 5 mM
sodium butyrate, 1x protease inhibitors in phosphate-buffered sal-
ine) and histones were isolated through acid extraction (0.2 M HCl
for 3 hours at 4 C). Standard sodium dodecyl sulfate–polyacryl-
amide gel electrophoresis (12–16% gels) and transfer onto 0.45-
lM polyvinylidene ﬂuoride membranes (Millipore, Watford, UK)
was used for Western blot. Membranes were blocked in 5% milk
and incubated overnight at 4 C with a primary antibody at
1:1000 dilution (rabbit H3K9ac; Abcam, Cambridge, UK or Cell Sig-
naling Technology, Danvers, MA) or rabbit H3 from Abcam). After 3
washes in Tris-buffered saline and 1% Tween, a secondary antibody
was used for 1 hour (1:5000, horseradish peroxidase–conjugated
anti-rabbit; GE Healthcare, Buckinghamshire, UK). The signal was
revealed after further washes using an ECL prime kit (GE Health-
care, Waukesha, WI) and visualized in a UVP GelDoc-It Imaging
system (Ultraviolet products, Upland, CA). For each major biologi-
cal question, a minimum of 3 was used per group, and at least 2
technical replicates (ie, 2 separate blots) were run in each case.
Blots were stripped and reprobed with an antibody against total
H3 to control for loading and nucleosome density. For quantiﬁca-
tion, band analysis was performed in ImageJ software (Open source
package, Wayne Rasband, NIH). In the case of duplets (Fig. 5A), the
top band was used for quantiﬁcation. The resulting H3K9ac/H3
ratios for each blot were averaged across technical replicates and
Fig. 5. Intrathecal HDACI treatment globally increased acetylation at lysine residue
9 of histone 3 (H3K9ac) in the dorsal spinal cord. Shown are representative Western
blots against H3K9ac after vehicle, MS-275 (MS30, MS60 at 30 nmol and 60 nmol/d,
respectively) and MGCD0103 treatment (MG30, MG60 at 30 nmol and 60 nmol/d,
respectively). Protein was obtained from ipsilateral dorsal spinal cord of animals
with neuropathy as a result of spinal nerve transection (A) or antiretroviral drug
injection (C). The blots were stripped and reprobed with an antibody against total
H3 as a loading control. (B, D) Quantiﬁcation of Western blot data using band-
density analysis in ImageJ software. Signiﬁcantly increased H3K9 acetylation was
observed in the nerve injury model after both MS-275 and MGCD0103 treatment
(n = 4, independent-sample t tests, P < .01) and in the drug-induced neuropathy
model after MS-275 treatment (n = 3, independent-sample t test, P = .017).
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obtained for biological replicates.
2.8. RNA extraction
Frozen tissue was homogenized in 500 lL Trizol, separated into
phases using chloroform and cleaned up with a Qiagen RNA micro-
kit (74004; Qiagen, Manchester, UK) following manufacturer’s
instructions. RNA quality was assessed on the Nanodrop (Thermo-
Fisher Scientiﬁc, Loughborough, UK) for organic contamination and
on the Agilent Bioanalyser (Agilent, Wokingham, UK) for
degradation.
2.9. Chromatin immunoprecipitation
Frozen tissue was thawed and cross-linked in 1% formaldehyde
for 10 minutes at room temperature. The reaction was quenched
by the addition of 0.125 M glycine. The homogenates were lysed
in 1% sodium dodecyl sulfate, 10 mM ethylenediaminetetraacetic
acid, 50 mM Tris (pH 8.1), 1x Roche complete protease inhibitors
and sonicated in a Diagenode bath sonicator (Bioruptor Diagenode,
Liege, Belgium) to obtain an average chromatin shear size of 250 to
500 bp. Chromatin immunoprecipitation was performed as de-
scribed before [57]. Brieﬂy, the sheared chromatin was incubatedovernight at 4 C with protein Gmagnetic beads (Dynabeads; Invit-
rogen, Paisley, UK) and 1 lg of the appropriate primary antibody
(anti-rabbit H3K9ac and anti-rabbit H3; Abcam). Rabbit immuno-
globulin G was used as a negative control. Completed ChIP reac-
tions were washed in standard wash buffers and Tris-EDTA (TE),
before being de-crosslinked (0.2 M NaCl at 65 C for 4 hours, fol-
lowed by incubation with proteinase K for 1 hour). ChIP DNA was
puriﬁed using Qiagen QIAquick PCR clean-up columns. One micro-
liter of each ChIP sample was used for subsequent quantitative
real-time polymerase chain reaction (qRT-PCR). Over the course
of the entire protocol, care was taken to avoid bias or batch effects
by processing treated and untreated samples in matched groups
and always with their appropriate internal controls (H3, immuno-
globulin G).
2.10. qRT-PCR
Ten microliters of standard qPCR reactions (Roche Light-
Cycler480 mix, 0.5 lM of primers) were run on a Roche Lightcycler
480 system. All primers were validated with standard curves to
test for appropriate efﬁciencies and melt curves, and their products
were checked on a gel. For cDNA, the 2^ddCT method [48] was
used with glyceraldehyde-3-phosphate dehydrogenase (Gapdh)
as a control. For ChIP samples, standard curves were run on every
plate to allow for absolute quantiﬁcation.
The following primers were used (50–30):
Gene desert: forward_TGTAAGGGCCCTCCATGTAAA, reverse_ATA
CTGCATAGGCCACATCTTTC
Cacna2d1: forward_AAAAGCACCACAAACCCCT, reverse_TTTGCA-
CAA TCTGGCTGG
Hdac1: forward_TAGCCTTCCCTCCAGGAGTC, reverse_GGGTAGCCT
GCGGTAATCTC
Hdac2: forward_ACACTTTCTTCTTGCCGCCT, reverse_CTCCCTCAG
CCCTCTTGTCT
Hdac11: forward_TCCAACACAGTCCTCACAGC, reverse_TCCAGCCCT
CTACACCCTAC
Rest: forward_TTAAAGCTCCACACGCACCT, reverse_GGGCCCAAG
TTTGCAAAGAG
Mecp2: forward_TGCTCCCTCCTTCTCCTCTC, reverse_AGCTTC-
GAG TGCTGAGGAAC
Desmin: forward_CAAGTGGAGGTCCTCACCAAC, reverse_TTTCCTCCT
GTAGCTTGGCCTT
Mt1a: forward_CCTCCTGCAAGAAGAGCTGC, reverse_AGCAGCACT
GTTCGTCACTT
Mt2a: forward_TGCAGCGATCTCTCGTTGAT, reverse_AGCAGGATC
CATCTGTGGCA
tRNA-cys: forward_GGGAGAAGCCTTAGTAGAGGAGA, reverse_GCC
TTAAGGTGATTATCATGTCGAA
Gapdh: forward_ATGGGAAGCTGGTCATCAAC, reverse_CCACAG
TCTTCTGAGTGGCA.
2.11. Microarray analysis
All tissue was taken from neuropathic animals, either drug or
vehicle treated. RNA from 4 biological replicates per group was
processed by UCL Genomics using an Ambion Whole transcript
Expression Kit (Invitrogen) and hybridized to Affymetrix Rat Gene
Arrays (Rat Gene 1.0ST) on a GeneChip Fluidics Station 450. Chips
were scanned on an Affymetrix GeneChip Scanner. Quality control
and subsequent analysis were carried out using the following
bioconductor packages in R: oligo [10] for preprocessing, RMA
normalization [34], and various quality controls (including MA
plots, box plots, and principal component analysis), limma [55]
for statistical analysis, and biomaRt [23] to access Ensembl v70
annotation. A recently characterized network reconstruction
Fig. 6. Intrathecal HDACi administration globally increased acetylation in rat spinal
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regulators of any gene expression changes [14]. Causal reasoning
uses directed molecular interactions (eg, protein X increases
expression of transcript Y) to identify upstream regulators whose
activity correctly explains a signiﬁcant proportion of the observed
gene expression changes. Importantly, causal reasoning takes into
account the direction of transcriptional change (up or down) seen
in the microarray data. Therefore, for a regulator to be signiﬁcant,
it must have both connections to differentially expressed genes
and the expression data must also support the relationship (in-
creases or decreases) between regulator and transcript. These
criteria result in causal reasoning being robust to random noise
[14] and can retrieve a signal where there is a consistent biolog-
ical underpinning. The algorithm was applied by B.S. without
previous knowledge of the speciﬁc HDACI compound used in this
particular dataset (MS-275).cord in a dose-dependent manner. MS-275 was administered to the spinal cord at
increasing doses (7.5–60 nmol/d), the protein extracted from dorsal lumbar
segments and probed with an antibody against the acetylated lysine residue 9 of
histone 3 (H3K9ac). Shown here is a representative Western blot with its
corresponding loading control against histone H3. Quantiﬁcation of 2 separate
blots with several biological replicates (n = 2–3) was performed using band-density
analysis in ImageJ software. Data are expressed relative to H3.3. Results
3.1. HDACI reduced mechanical and thermal sensitivity after nerve
injury
Vehicle or HDACI was delivered intrathecally to adult rats
5 days before and continuously throughout nerve injury–induced
neuropathic pain. Two different class I HDACIs (MS-275 and
MGCD0103) were used, and both were found to signiﬁcantly atten-
uate mechanical hypersensitivity after injury by 40% to 50%
(Fig. 1). This result was obtained across 4 independent experi-
ments; in every one of them, the testing was carried out blind to
experimental groups. Figure 1A shows a summary of all data, and
Figures 1B and D show the effect of drug treatment on L5 spinal
nerve transection and Figure 1C on partial sciatic nerve ligation.
Group sizes ranged from 6 to 8 in individual studies, and results
were statistically signiﬁcant at a minimum of P < .05 (see Fig. 1 leg-
ends for more detail). Delivery of the HDACI before any insult had
no effect on sensitivity thresholds, and the rats were ostensibly
normal, with no obvious side effects.
In the L5 spinal nerve transection model, thermal sensitivity
thresholds were also assessed (Fig. 3). The HDACI MS-275 signiﬁ-
cantly attenuated the injury-induced decrease in withdrawal
thresholds in response to heat at both doses tested (n = 6, P < .05).
Pretreatment with HDACI before the insult was necessary for
the observed analgesic effect to occur. When pumps were con-
nected only after L5 spinal nerve transection, MS-275 could no
longer affect mechanical thresholds (Fig. 4), suggesting that HDA-
CIs, at least in this very speciﬁc paradigm, hold little promise as
therapeutic targets.
3.2. HDACI reduced mechanical hypersensitivity in a more clinically
relevant model of antiretroviral drug–induced neuropathy
Histone acetylation may also be involved in the generation of
nontraumatic peripheral neuropathy. The antiretroviral drug d4T
causes dieback of sensory axons from the periphery, reduces dor-
sal horn expression of calcitonin gene-related peptide and IB4
[32] and is often associated with severe and chronic neuropathic
pain [9,56,62]. Some of the current authors (W.H. and A.R.) previ-
ously characterized d4T-induced neuropathy in the rat [32]. Using
their model, the present study found that pretreatment and long-
term administration of HDACI signiﬁcantly increased hind limb
withdrawal thresholds to punctate mechanical stimuli compared
with vehicle controls (n = 7, P < .05) (Fig. 2). The magnitude of
the effect was similar to that observed in nerve injury models,
reducing the animals’ hypersensitivity to external stimulation
by 40% to 50%.3.3. HDACIs affected H3K9 acetylation in the spinal cord but not the
dorsal root ganglia
As expected, intrathecal treatment with MS-275 and
MGCD0103 increased spinal acetylation of histones due to the
HDACs not being able to exert their effect. Using Western blot, glo-
bal acetylation was measured at lysine residue 9 and found to be
signiﬁcantly increased in injured dorsal lumbar cord after drug
administration. The effect was dose dependent (Fig. 6), reaching
a ceiling at 30 nmol/d and could be observed in both traumatic
and drug-induced models (Fig. 5).
Interestingly, the drugs did not appear to reach the dorsal root
ganglia (DRG) relevant for hind limb sensitivity (L4–6) at detect-
able concentrations, possibly due to high catheter placement. Thus,
Western blots of L5 DRG showed no clear difference in acetylation
between drug-treated and nondrug-treated tissue (Fig. 7). Equally,
examining H3K9 acetylation at individual promoters revealed in-
creases only in spinal cord, but not L5 DRG tissue (Fig. 8).
Six genes were chosen for testing with ChIP-qPCR: the 2 most
prominent class I HDACs (Hdac1 and Hdac2); Hdac11, which
should not be affected by MS-275 [7]; the calcium channel subunit
a2d1 (Cacna2d1), as one of the genes known to be greatly trans-
criptionally dysregulated after neuropathic injury [21]; and 2 tran-
scription factors that have been implicated in the epigenetic
regulation of pain conditions (Rest and Mecp2 [27,59]). None of
them displayed signiﬁcant acetylation changes at lysine residue 9
in the DRG (Fig. 8B), although clear changes could be observed in
the spinal cord (Fig. 8A). Independent t tests were statistically sig-
niﬁcant for Cacna2d1 (P = .047) and Mecp2 (P = .016) and nearly
signiﬁcant for Hdac1 (P = .074). Considering the high variability
associated with the ChIP-qPCR technique and the very heteroge-
neous cell populations of the spinal cord, differences of this magni-
tude are unlikely to be due to type I errors, even though they did
not survive stringent Bonferroni correction.
Finally, microarray analysis of RNA extracted from HDACI or
vehicle treated, injured L5 DRG was undertaken. Ipsilateral injured
DRG were analyzed in 4 biological replicates per group. All RNA
samples and Affymetrix arrays passed quality control. However,
the microarrays revealed no signiﬁcant changes in expression
after multiple comparison corrections. Even at a very permissive
threshold, of unadjusted P < .01, only 8 genes showed any change
in expression above 1.5-fold (Table 1 and Supplementary Table
Fig. 7. With the intrathecal delivery method used, HDACI did not appear to have a
measurable effect on dorsal root ganglion (DRG) acetylation, suggesting that the
mechanism of action was mostly central. (A) Representative Western blot of single
rat L5 DRG after nerve transection and intrathecal vehicle or HDACi treatment. Total
H3 was used as a loading control for acetylated H3K9. (B) Quantiﬁcation of global
H3K9ac revealed no difference between vehicle and HDACI treatment groups (n = 4,
P = not signiﬁcant [n.s.]).
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recently characterized network approach called causal reasoning
(see Section 2 and Ref. [14]). The algorithm is more robust toFig. 8. ChIP–quantitative polymerase chain reaction (qPCR) revealed changes in H3K9ac
ganglia (DRG). (A) ChIP-qPCR of dorsal ipsilateral spinal cord tissue examining H3K9ac at
gene desert control region and the transcriptional start sites of 6 genes: Hdacs1, 2, and 1
and Mecp2. Histone deacetylase inhibitor resulted in increased enrichment at 4 of 6 of
independent-sample t tests, uncorrected P = .016, P = .047, respectively). (B) In the DRG
between treatment groups at any of the genes tested. ⁄P < 0.05, #P < 0.1.random noise because it identiﬁes upstream regulators of differen-
tially expressed genes and takes into account the direction of
molecular interactions. Despite this, no regulators or networks
emerged as signiﬁcant in the DRG that could conceivably be related
to abnormal HDAC activity (data not shown).
Taken together these results suggest that, with the speciﬁc
intrathecal delivery protocol described, HDACIs most likely exerted
the majority of their effects centrally at the level of the spinal cord.
3.4. Microarray analysis of spinal cord mRNA exposed the speciﬁc
signature of MS-275 and suggested that the drug’s transcriptional
effect was mediated through HDAC1
In contrast to the DRG, microarray analysis of the spinal cord
after nerve injury offered a more interesting picture. RNA from
dorsal ipsilateral lumbar segments, treated with vehicle or HDACI,
was hybridized to Affymetrix microarrays (n = 4). Again, all chips
passed standard quality controls, but principal component
analysis showed little separation between groups. Unlike in the
DRG, this was a less surprising outcome. Even with drastic
interventions such as nerve injury or complete Freund’s adjuvant,
research commonly only reports small fold changes (<2) in the
spinal cord, most likely due to high tissue heterogeneity
[28,39,53].
Only a single gene passed standard false discovery rate
correction (FDR) at P < .05: ENSRNOG00000033932, a mitochon-
drial cysteine transfer RNA (tRNA-cys), signiﬁcantly upregulated
after HDACI treatment. A larger, but still modest list of nominallywith drug treatment at several promoters in the spinal cord, but not the dorsal root
relevant promoters. Shown here is the ratio of enrichment of H3K9ac over H3 for a
1; the calcium channel subunit a2d1 (Cacna2d1), and the transcription factors Rest
the genes tested, statistically signiﬁcant in the case of Cacna2d1 and Mecp2 (n = 4,
, MS-275- and vehicle-treated ipsilateral DRG revealed no signiﬁcant differences
Table 1
Summary counts of differentially expressed genes in ipsilateral dorsal cord and ipsilateral DRG at 2 levels of stringency: an FDR-corrected P value < .05 and an uncorrected P
value < .01.
Stringency Down No change Up
FDR correction, P < .05 Spinal cord 0 29,213 Mitochondrial transfer RNA ENSRNOG00000033932
4.55x upregulated
DRG 0 29,214 0
No FDR correction, P < .01
At any fold change Spinal cord 180 28,835 199
DRG 103 29,051 60
At fold change P 1.5 Spinal cord 12 29,184 18
DRG 4 29,206 4
DRG, dorsal root ganglia; FDR, false discovery rate.
Note: Microarray analysis of RNA extracted from histone deacetylase inhibitor– or vehicle-treated injured tissue (n = 4) revealed only a single gene that survived multiple
testing corrections: a mitochondrial transfer RNA in the spinal cord with EnsemblID ENSRNOG00000033932. At a very permissive threshold of uncorrected P < .01, a small
number of genes showed signiﬁcant changes: 379 in the spinal cord and 163 in DRG. Due to the potential for false positives in this list, these genes were only used for causal
reasoning analysis, which is robust to random noise.
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Supplementary Table), a threshold at which false positives can
undoubtedly pass. Again, therefore, genes were not examined indi-
vidually, but analyzed further using causal reasoning to retrieve
signals with consistent biological underpinning. Of the nominally
signiﬁcant probes, 177 were annotated with an Ensembl ID and
had an unequivocal ortholog in humans. Of those, 83% were pres-
ent in the knowledge base of causal interactions that forms the ba-
sis for the causal reasoning algorithm.
The top causal hypothesis that emerged from the analysis
was for an increase in the compound MS-275 (Bonferroni cor-
rected P = .0026), which could be connected to 28 of the 177
genes (Fig. 9 and Table 2). This means that the changes observed
in the microarray analysis matched previously reported changes
induced by MS-275 and can be said to carry the ‘‘signature’’ of
this particular HDACI. A reassuring result-demonstrating that
causal reasoning could successfully discriminate relevant path-
ways from any noise. Of further interest in the top 10 causal
regulators was the hypothesized decrease in HDAC1, which
could be connected to 32 genes, 27 of them with correct direc-
tionality. HDAC1 is one of the primary targets of MS-275, and
these results suggest that a signiﬁcant proportion of the expres-
sion changes observed were due to its impaired function after
drug administration.
To validate some of these microarray results, qRT-PCR was car-
ried out on an independent cDNA batch to test expression of 3
downstream targets of HDAC1 action, as well as the signiﬁcantly
dysregulated tRNA-cys (Fig. 10). Two metallothioneins, Mt1a and
Mt2a, and the intermediate ﬁlament desmin showed a 2.5- to 3-
fold increase in expression, further supporting a small, but robust
effect on HDAC1 target genes. Equally consistent with the array
data, tRNA-cys was increased 1500-fold in HDACI-treated tissue,
representing a highly signiﬁcant increase at P = .00013.
4. Discussion
The data presented provide the ﬁrst direct evidence of a role for
histone deacetylases in the development of neuropathic pain con-
ditions. Delivery of HDACI into rat spinal cord was found to reduce
hind paw hypersensitivity by 40% in several different models of
neuropathic pain: partial sciatic nerve ligation, L5 spinal nerve
transection, and a systemic model of antiretroviral drug–induced
neuropathy with quite different progression and neuropathology
[32]. These results are in line with recent work reporting analgesic
effects of HDACI in acute inﬂammatory models [2,13,65].
In contrast, drug treatment did not affect already established
neuropathic pain after spinal nerve transection, suggesting that
histone acetylation might be speciﬁcally involved in the emer-gence of hypersensitivity. To dissociate this further, future experi-
ments could be conducted in which drug pretreatment is stopped
at the time of injury. It also cannot be completely ruled out that an
effect might appear at a higher dose, even though the threshold for
full global hyperacetylation appeared to have been reached at the
30-nmol/d dose used in this study.
On a mechanistic level, it seems likely that HDACIs exerted their
effect centrally within the spinal cord. No evidence could be found
for involvement of the DRG, with the compounds having no clear
effects on injured tissue in terms of global histone acetylation, local
promoter acetylation, or RNA expression levels. This does not nec-
essarily mean that neuropathic pain processes in the DRG cannot
be modulated by epigenetic mechanisms, but only that they were
not affected in this particular case, most likely because catheters
were placed optimally to treat the lumbar spinal cord and there-
fore were relatively far from L5 ganglia.
In contrast, at the level of the spinal cord, HDACI signiﬁcantly
increased H3K9 acetylation and altered mRNA expression.
H3K9ac levels were affected both globally (as measured by Wes-
tern blot) and locally at various relevant promoters (as measured
by ChIP). Microarray analysis revealed a mitochondrial transfer
RNA as signiﬁcantly upregulated in drug-treated tissue. Moreover,
the expression pattern of a nominally signiﬁcant list of genes was
consistent with an MS-275 signature as well as a decrease in
HDAC1 function.
Of note, MS-275 did not directly affect acetylation at all pro-
moters tested, despite its selectivity for the ubiquitous class I
HDACs [7]. Of 6 genes tested, changes were observed in 4 (Hdac1,
Cacna2d1, Rest, Mecp2), 2 of which were statistically signiﬁcant at
P < .05: Mecp2 and Cacna2d1. Mecp2 (methyl-CpG-binding pro-
tein) methylates DNA and can thus lead to transcriptional silenc-
ing. There is evidence to suggest that MeCP2 might act as a
global regulator of chromatin structure, its joint presence with
HDACs in repressor complexes enabling it to inﬂuence acetylation
and allowing a link between acetylation and DNA methylation pat-
terns [54]. The increased acetylation at MeCP2 could therefore be
the system’s attempt to counterbalance diminished HDAC action
after drug administration.
The functional effect of increased H3K9ac at the calcium chan-
nel subunit Cacna2d1 is less clear. The gene is known for abnormal
increases in transcription after neuropathic pain [21], and the
microarray data presented here suggest that these were un-
changed with HDACI administration. Hence, in this case, local
H3K9 acetylation clearly failed to correlate with transcription. It
could be that at the Cacna2d1 promoter, H3K9ac does not have
any real biological signiﬁcance: the overall enrichment was very
small, barely exceeding the negative control levels of a gene desert
region. The study of other marks posited to correlate with tran-
Fig. 9. Causal reasoning applied to spinal cord microarray data revealed an MS-275 signature and suggested that the effect of this particular HDACI was mediated through
HDAC1. Shown here are the causal networks for MS-275 (A) and HDAC1 (B). Yellow nodes represent the upstream regulators. Red and green nodes are genes in the nominally
signiﬁcant list of transcripts that were observed to increase or decrease in expression, respectively. Blue nodes are intermediaries introduced by the algorithm and can be
either proteins or biological processes. The arrow and bar edge endings indicate an activating or repressive relationship, respectively. Genes chosen for further validation were
MT1E (rat ortholog Mt1a), MT1H (rat ortholog Mt2a), and desmin.
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revealing. Either way, HDACIs are unlikely to exert their effect by
reversing the abnormal transcriptional regulation of Cacna2d1.
Generally, the measurable effect of HDACI treatment on tran-
scription was modest, although the emergent MS-275 signature
suggested that expected changes did occur, and causal reasoning
further suggested that they were mediated through decreased
HDAC1 function. This was also conﬁrmed by qRT-PCR, which
showed increased expression of several HDAC1 targets.
MS-275 administration did not affect HDAC1 itself at day 14
(fold ‘‘change’’ of 1.06). It could be that an earlier effect on tran-
scription was missed, although a different explanation seems more
likely given what is known about HDACI function. These com-
pounds block access of histone lysine residues to the active site
of HDACs [25], and their effects may differ depending on whichparticular HDACI protein complex they are incorporated into [3].
In this case then, MS-275 may have blocked HDAC1 from accessing
and binding to its usual targets, affecting expression of a variety of
genes downstream. Perhaps the hint of increased H3K9 acetylation
observed at the HDAC1 promoter itself could be interpreted as the
system’s attempt to counteract the drug-induced blockade of
HDAC1 function.
Only a single gene survived multiple comparison corrections
and was signiﬁcantly changed in MS-275 treated tissue: a mito-
chondrial cysteine transfer RNA, the relative expression of which
was increased by nearly 5-fold in the microarray and 1500 times
in subsequent qRT-PCR. Transfer RNAs are essential for the transla-
tion of speciﬁc amino acids, in this case of cysteine in the mito-
chondrial genome [52,64]. There appears to be no literature
linking these RNAs to HDACIs, histone acetylation, or chronic pain.
Table 2
MS-275 and HDAC1 emerged as mediators of gene expression changes using causal
reasoning on 177 nominally signiﬁcant genes.
Hypothesis P (Bonferroni) Enrichment C I A Type
MS-275+ 2.63E06 (0.029) 1.81E05 21 5 2 Chemical
Roscovitine 1.27E05 (0.141) 3.04E05 19 5 5 Chemical
HDAC1 1.42E04 (1.569) 8.81E03 19 5 8 Protein
DHEA
sulfate
1.34E03
(14.848)
8.77E05 26 12 7 Chemical
SMAD3+ 2.06E03
(22.797)
1.81E04 26 12 10 Protein
TLR2+ 3.44E03
(38.013)
4.86E03 28 14 12 Protein
LY294002 4.22E03
(46.638)
3.60E03 31 16 23 Chemical
ADRB2+ 4.34E03
(47.967)
9.56E04 29 15 12 Protein
SNCA+ 8.07E03
(89.172)
1.62E03 28 15 12 Protein
A, number of ambiguous connections; C, number of causally correct paths from the
hypothesis to the differentially expressed genes; DHEA, dehydroepiandrosterone;
HDAC, histone deacetylase inhibitor; I, the number of incorrect paths.
Note: The sign in the hypothesis column indicates whether an increase (+) or
decrease () in the activity of the hypothesis is predicted to cause the observed
expression changes. The P column contains the unadjusted P values, with Bonfer-
roni-adjusted P values in parentheses. This test takes into account the directionality
of the fold changes. In contrast, the Enrichment column P values reﬂect the pro-
portion of downstream regulators present in the gene expression dataset.
Fig. 10. Quantitative real-time polymerase chain reaction (qRT-PCR) validation of
spinal cord microarray data conﬁrmed increased expression of (HDAC)1 targets and
of a mitochondrial transfer RNA. Primers were designed against HDAC1 targets (2
metallothioneins [Mt1a, Mt2a, human orthologs: MT1E, MT1H] and desmin) as well
as the cysteine transfer RNA (tRNA-cys) identiﬁed via microarray. All values were
normalized to Gapdh (2^-ddCT), and relative expression values were calculated in
relation to the vehicle average. Increased transcription was observed in drug-
treated tissue, highly signiﬁcant in the case of tRNA-cys: uncorrected P values of
.027 (Mt1a), .026 (Mt2a), .047 (desmin), and .00013 (tRNA-cys); independent-
sample t tests, n = 4.
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opment of chronic pain conditions, such as chemotherapy-induced
neuropathy [26,63]. Moreover, in the d4T model speciﬁcally, it has
been shown that abnormal regulation of mitochondrial proteins
might contribute to the degeneration of distal axons [32]. Yet, it still
remains to be seen whether any of this relates speciﬁcally to transfer
RNAs and hence whether there could be a real biological connection
between this speciﬁc cysteine-tRNA and neuropathic pain.
In summary, only limited effects of HDACI on transcription
were observed in this study, which might be due to the mix of cell
types and the complexity of the systems involved. HDAC inhibition
is often simplistically equated with hyperacetylation and hence in-
creased transcription. Yet, the regulation of histone acetylation is a
very intricate, highly cell type–speciﬁc process involving not only
HATs and HDACs, but also multiple other cellular proteins and pos-
sibly even microRNAs [33,50].
HDACs themselves are a large family of 4 classes: zinc-depen-
dent classes I, II, and IV and the biochemically quite distinct class
III or sirtuins. Although class I HDACs (HDAC1–3) are ubiquitously
expressed, they are currently the only zinc-dependent HDACs that
inhibitors can convincingly target in a select fashion [7] and weretherefore chosen for this study. HDAC4, HDAC5, and HDAC11 also
show high expression levels in the central nervous system [8], but
their function would have to be elucidated with genetic or trans-
genic approaches.
There is convincing evidence from work on yeast and T cells
that HDACs can be associated with gene activation as well as
repression [37,60], and HDAC function is thought to be very dy-
namic and context dependent [4,17]. Deacetylase enzymes, in par-
ticular classes II and III, also act on cytoplasmic proteins and are
thus able to inﬂuence a wide range of processes including transla-
tion, microtubular transport, and membrane regulation [45].
Perhaps as a consequence of this, HDACIs are reported to have dif-
ferential impact on H3K9 acetylation depending on promoter status
(active, poised, or silent) [60] and are known to have relatively mod-
est effects on transcription [30,44], possibly due to a limited supply
of transcriptional machinery [54]. These ﬁndings, combined with the
generally small fold changes observed in highly heterogeneous
spinal cord tissue [28,39], lead one to expect difﬁculties in teasing
out biologically relevant expression changes after HDACI treatment.
Technical advances, such as cell sorting techniques like ﬂow cytom-
etry, could help resolve some of these issues in the future.
It remains to be seen whether nerve injury itself changes his-
tone acetylation or indeed other modiﬁcation marks in the spinal
cord. Given that HDACI can positively affect hypersensitivity in
the models described here, this possibility certainly presents itself
as a major hypothesis, albeit a challenging one to explore. Address-
ing it directly will most likely require genomewide data from ChIP-
seq and, even more so than in the case of transcription, thorough
cell type–speciﬁc analysis.
4.1. Conclusions
This study has explored the potential involvement of an epige-
netic process in chronic neuropathic pain. Although the precise
mechanisms still remain to be determined, the resulting data
strongly suggest that chemical interference with histone acetyla-
tion at the level of the spinal cord can ameliorate the sensory
abnormalities associated with both traumatic nerve injury and
drug-induced neuropathy.
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